Establishment Labs (NASDAQ:ESTA) Price Target Increased to $60.00 by Analysts at Citigroup

Establishment Labs (NASDAQ:ESTAFree Report) had its price target upped by Citigroup from $49.00 to $60.00 in a report published on Wednesday, Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Mizuho upped their target price on shares of Establishment Labs from $50.00 to $65.00 and gave the stock a buy rating in a research note on Monday. Stephens reiterated an overweight rating and issued a $47.00 target price on shares of Establishment Labs in a report on Thursday, January 11th. Finally, JPMorgan Chase & Co. upped their price target on Establishment Labs from $46.00 to $53.00 and gave the stock an overweight rating in a report on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $63.33.

Check Out Our Latest Report on ESTA

Establishment Labs Trading Up 4.6 %

Shares of NASDAQ ESTA opened at $52.79 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 10.26. The stock has a market capitalization of $1.44 billion, a PE ratio of -17.37 and a beta of 1.24. Establishment Labs has a twelve month low of $16.96 and a twelve month high of $79.88. The stock has a fifty day simple moving average of $43.58 and a 200-day simple moving average of $35.96.

Establishment Labs (NASDAQ:ESTAGet Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.16. The company had revenue of $31.60 million during the quarter, compared to the consensus estimate of $31.44 million. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. Establishment Labs’s revenue was down 27.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.55) EPS. On average, equities analysts forecast that Establishment Labs will post -1.58 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Large investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. boosted its position in shares of Establishment Labs by 17.2% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 80,000 shares of the company’s stock worth $3,926,000 after acquiring an additional 11,736 shares in the last quarter. Legato Capital Management LLC boosted its holdings in Establishment Labs by 63.1% in the fourth quarter. Legato Capital Management LLC now owns 8,438 shares of the company’s stock valued at $218,000 after purchasing an additional 3,263 shares in the last quarter. Bamco Inc. NY increased its stake in Establishment Labs by 29.0% in the third quarter. Bamco Inc. NY now owns 333,777 shares of the company’s stock valued at $16,378,000 after purchasing an additional 75,000 shares during the last quarter. Sei Investments Co. raised its holdings in Establishment Labs by 11.6% during the second quarter. Sei Investments Co. now owns 44,567 shares of the company’s stock worth $3,058,000 after purchasing an additional 4,632 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of Establishment Labs by 41.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 368,407 shares of the company’s stock worth $18,078,000 after buying an additional 107,441 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

(Get Free Report)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

See Also

Analyst Recommendations for Establishment Labs (NASDAQ:ESTA)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.